Great Novel Therapeutics Biotech & Medicals (7427.TWO)

Great Novel Therapeutics Biotech & Medicals (7427.TWO) — VMCI valuation read

Great Novel Therapeutics Biotech & Medicals sits at VMCI 32/100, with the Healthcare sector median at 50. That 18-point spread is the first thing to note on 7427.TWO: it tells the reader the composite is unfavorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on 7427.TWO are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on 7427.TWO: 7427.TWO trades at 22.0x earnings, 22% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.7x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

7427.TWO rose 3.6% over the trailing 7 days, with a -2.4% read on a 30-day basis.